Introduction {#s1}
============

It remains unknown how both intron removal and exon rearrangement are precisely regulated to produce correct proteomes in a cell type- or developmental stage-specific manner. Alternative splicing, the process by which the exons of primary transcripts can be spliced into different arrangements to produce structurally and functionally distinct mRNA and protein variants, is the most widely used mechanism to enhance the protein diversity of higher eukaryotic organisms. It has been estimated that 35%--94% of all human genes appear to undergo alternative splicing [@pone.0004732-Mironov1]--[@pone.0004732-Wang1], suggesting that this mechanism has a major role in generating protein diversity. As sequence data continue to be generated from projects at an ever-increasing rate, the need for mining the data and constructing a repository for transcriptome information continues to grow as well.

In many pathological conditions, aberrantly spliced pre-mRNAs are generated because they escape the quality control mechanisms within cells (e.g. the nonsense mediated mRNA decay pathway) and are, therefore, translated into aberrant proteins involved in human diseases, including cancer [@pone.0004732-Venables1]--[@pone.0004732-Caceres1]. It is estimated that approximately 60% of disease mutations in the human genome are splicing mutations [@pone.0004732-LopezBigas1], [@pone.0004732-Xing1]. Currently, the analysis of cancer-specific alternative splicing is a promising step forward and potential source of new clinical diagnostic, prognostic, and therapeutic strategies. Evidence is accumulating that supports a connection between tumorigenesis and alternative splicing [@pone.0004732-Kim2]--[@pone.0004732-Roy1]. Using bioinformatic approaches, Xu and Lee discovered cancer-specific splice variants in 316 genes [@pone.0004732-Xu1]. We previously identified testis-/testis cancer-specific splice variants using bioinformatic and experimental approaches [@pone.0004732-He1].

Despite the growing interest in the impact of alternative splicing in various aspects of the biological processes, our understanding of alternative splicing is still scattered, and its general regulatory mechanisms, especially in tumorigenesis, are not well known [@pone.0004732-Takeda1], [@pone.0004732-Ladd1]. However, it is believed that cancer-specific splice variants could be involved in the etiopathogeny of many diseases and some might serve as diagnostic or prognostic markers. Moreover, the direct targeting of protein is probably an advantageous way of correcting cancer-associated splicing alterations. For example, the cancer-restricted splice variant protein could be used as the target for specific antibodies conjugated to tumor cell toxins for cancer treatments. The etiopathogeny concerning the cancer-specific AS and all related applications need to be explored further.

In order to advance our understanding of the biological significance of alternative splicing in human cancers, it is essential to systematically identify cancer-specific splicing events at the transcriptome level. In the present study, we performed a genome-wide analysis of alternative splicing in human cancer and normal tissues using an intersection/subtractive model consisting of the following steps: 1) identifying insertions or deletions in the alignments of expressed sequence tags (ESTs) to identify alternative splicing transcripts based on a previously described method [@pone.0004732-Brett1], 2) the alignment of EST/genome to confirm the transcripts, and 3) obtaining the tissue-specific and alternatively spliced variants by subtractively cross-screening the alternatively spliced transcripts in each tissue. Our results distinguish distinctive patterns of cancer-specific alternative splicing and identify a large number of cancer- and tissue-specific splicing isoforms, which provides a global view of human cancer-specific alternative splicing in a large-scale approach and a potential source of new clinical diagnostic, prognostic, and therapeutic strategies for human cancer.

Materials and Methods {#s2}
=====================

Data sources and filtration {#s2a}
---------------------------

Human EST data for both cancerous and normal tissues were drawn from the Cancer Genome Anatomy Project (CGAP) (<http://cgap.nci.nih.gov/Tissues/LibraryFinder>). The CGAP collects EST libraries from all over the world and provides good tissue information. All available EST libraries for both human cancer and normal tissues were downloaded from the CGAP libraries, Mammalian Gene Collection libraries, and Open Reading Frame EST Sequencing libraries. We sought to avoid mixing multiple tissues. Among these libraries, those signed 'pooled' were excluded because these procedures affect tissue classification. For normal tissue, ESTs were classified in accordance with the developmental stage information, and libraries without this information were not used. All EST and library data on different tissues that were used are listed in [Tables 1](#pone-0004732-t001){ref-type="table"} and [2](#pone-0004732-t002){ref-type="table"}.

10.1371/journal.pone.0004732.t001

###### Numbers of libraries and ESTs in cancers.

![](pone.0004732.t001){#pone-0004732-t001-1}

  Cancer types (27 types)                    Libraries       ESTs
  ----------------------------------------- ----------- ---------------
  adrenal_cancer                                 3           10431
  bone_marrow_leukemia                          21           43943
  brain_glioma                                  43           75546
  brain_meningioma                               7            860
  brain_cancer                                  213          39845
  breast_cancer                                 792         143423
  cervical_cancer                               32           48606
  chondrosarcoma                                15           49638
  colorectal_cancer                             803         185632
  esophageal_cancer                             17           15039
  germ_cell_cancer                              30          161682
  head_and_neck_cancer                          291          93978
  kidney_cancer                                 87           74290
  liver_cancer                                  62          117276
  lung_cancer                                   220         126775
  lymphoma                                       6           12458
  muscle_tissue_cancer                          26           83411
  ovarian_cancer                                162          98087
  pancreas_insulinoma                            1           33046
  pancreatic_cancer                             22           82994
  primitive_neuroectodermal_cancer_of_CNS       23           72677
  prostate_cancer                               169         168151
  prostatic_intraepithelial_neoplasia            5           9569
  retinoblastoma                                 3           51568
  skin_cancer                                   36          137803
  stomach_cancer                                244          94950
  uterus_cancer                                 110          46624
  **Total**                                  **3,443**   **2,078,302**

10.1371/journal.pone.0004732.t002

###### Numbers of libraries and ESTs in normal tissues.

![](pone.0004732.t002){#pone-0004732-t002-2}

  Tissue type (35 tissues)     Libraries       ESTs
  --------------------------- ----------- ---------------
  bone-adult                       2           1965
  brain-adult                     368         130619
  brain-fetus                     73          174889
  brain-infant                    11           73726
  colon-adult                     133          25757
  colon-fetus                      1             5
  eye-adult                       33          100173
  eye-fetus                        7           19659
  heart-adult                     10           3979
  heart-fetus                     13           62681
  kidney-fetus                    16           13947
  liver-adult                     11           29818
  liver-fetus                     22          142750
  lung-adult                      92           44457
  lung-fetus                      18           35607
  mammary-gland-adult             331          68603
  muscle-adult                    10           70211
  muscle-fetus                     4           2235
  ovary-adult                      6           8126
  pancreas-adult                  10           24759
  pancreas-fetus                   2           5545
  peripheral-nerve-adult           1           6571
  peripheral-nerve-juvenile        1           9482
  pituitary-gland-adult            6           8520
  placenta-adult                  358         268277
  prostate-adult                  127          53220
  skin-infant                      3           10319
  spleen-adult                     3           1841
  spleen-fetus                     1           1332
  stomach-adult                   67           10417
  stomach-fetus                    2             9
  testis-adult                    157          30549
  thyroid-adult                   78           13314
  uterus-adult                    10           35026
  vascular-adult                   5           8451
  **Total**                    **1,992**   **1,496,839**

All collection data were then dealt with in three procedures: repeat sequence masking to remove simple repeats in the dataset (program, repeatmasker; repeat database, repbase; girnst server:[www.girinst.org](http://www.girinst.org)), vector and contamination masking to clean the vector sequences (program, crossmatch; vector database, UniVec_Core; National Center for Biotechnology Information ftp server: [ftp://ftp.ncbi.nih.gov/](http://ftp://ftp.ncbi.nih.gov/)), and a final cleaning of short and rubbish sequences (program, seqclean from egassembler server: <http://egassembler.hgc.jp>). Any Alu repeats were included in, and the filtered ESTs were available for the following analysis.

Computational procedures to identify cancer/tissue-specific alternative splicing {#s2b}
--------------------------------------------------------------------------------

A basic local alignment search tool (BLAST) database was constructed for the ESTs of each tissue. Alternative splicing was analyzed based on a previous method [@pone.0004732-Brett1]. Transcripts specific to tissue T were identified based on an intersection/subtractive model:

Where ***TS*** is the alternatively spliced transcripts specific to tissue T, ***T*** is all transcripts in tissue T, and ***O*** is all transcripts in the other tissues (**∩**, intersection).

Briefly, the three steps were as follows:

1.  Tissue T\'s EST dataset was BLASTed against itself. The e-value was set to 1e-30. Gaps (insertion or deletion) in the ESTs were identified after alignment. Parameters to identify alternative splicing: the gap length, 10 bp; nucleotide identity, 95%.

2.  Tissue T\'s ESTs were BLASTed against the ESTs of the other tissues. Parameters were the same as step 1.

3.  Subtractive ESTs were identified as tissue T-specific ESTs by insertion/deletion comparisons after BLAST. Computer programs were written using the Perl language.

EST/genomic sequence alignments, chromosome mapping, and splice site analysis {#s2c}
-----------------------------------------------------------------------------

To decrease errors in EST alignments and determine the chromosomal loci of each gene, we localized ESTs to genomic sequences using BLAST-like alignment tools (<http://genome.ucsc.edu>). We used the default parameters and selected the best score results. The exon position on the chromosome was recorded for each transcript and used to determine splice sites and gene structure. Splice sites for both 5′ and 3′ exon/intron boundaries were aligned online via <http://weblogo.berkeley.edu/logo.cgi>. We allowed an error of 10 bp in the exon/intron boundary. Based on comparisons of EST/genomic alignments, two possible errors can be checked: (i) if the candidate EST in the same gene was not on the same chromosome and (ii) is the candidate EST in the same gene was not in the same locus on the chromosome. The reasons for these errors mainly included EST sequencing errors, pseudogenes, and multiple copy genes. The two cases were excluded as false positives in the final database.

Function classification of alternative splicing {#s2d}
-----------------------------------------------

Each alternatively spliced EST was BLASTed to the RefSeq mRNA database (expectations 1e-30) to identify the corresponding genes. Using PANTHER (<http://www.pantherdb.org/tools/genexAnalysis.jsp>), these genes were clustered by the gene ontology (GO) process. We also searched the Entrez Gene Database to correct our results.

Alternative splicing database construction {#s2e}
------------------------------------------

We input all prediction results into the local alternative splicing database. This database was constructed with MySql and programmed by Perl and CGI. All information such as gene ID, gene structure, EST accession, mRNA accession, gene information, and exon location on the chromosome were collected in the database.

Results {#s3}
=======

HCSAS: A database for cancer-specific alternative splicing {#s3a}
----------------------------------------------------------

For analyzing cancer-specific alternative splicing, we carefully classified all available EST libraries into 35 distinct normal tissue classes and 27 types of cancer to avoid mixing multiple tissues. Our final classification consisted of 1,992 libraries with 1,496,839 ESTs for normal human samples and 3,443 libraries with 2,078,302 ESTs for cancer samples ([Tables 1](#pone-0004732-t001){ref-type="table"} and [2](#pone-0004732-t002){ref-type="table"}). Through computationally subtractive analysis, we detected 15,093 cancer-specific transcripts in 9,989 genes from the 27 types of cancer, and 14,376 normal tissue-specific transcripts in 7,240 genes from the 35 tissues ([Tables 3](#pone-0004732-t003){ref-type="table"} and [4](#pone-0004732-t004){ref-type="table"}), which cover the main types of human tumors and tissues. Cancer-specific transcript numbers per gene detected were 1 to 1.69 with an average of 1.51, whereas there were 1 to 6 normal tissue-specific transcripts with an average of 1.99 ([Tables 3](#pone-0004732-t003){ref-type="table"} and [4](#pone-0004732-t004){ref-type="table"}), indicating fewer alternative splicing events (cancer-specific) in cancer compared to normal tissues.

10.1371/journal.pone.0004732.t003

###### Numbers of cancer-specific AS transcripts and their genes.

![](pone.0004732.t003){#pone-0004732-t003-3}

  Cancer types (27 types)                      Genes     Transcripts   Transcripts/Gene
  ----------------------------------------- ----------- ------------- ------------------
  adrenal_cancer                                61           80              1.31
  bone_marrow_leukemia                          237          356             1.50
  brain_glioma                                  485          720             1.48
  brain_meningioma                               1            1              1.00
  brain_cancer                                  22           30              1.36
  breast_cancer                                 550          757             1.38
  cervical_cancer                               316          428             1.35
  chondrosarcoma                                239          352             1.47
  colorectal_cancer                             397          578             1.46
  esophageal_cancer                             175          226             1.29
  germ_cell_cancer                             1307         2167             1.66
  head_and_neck_cancer                          135          182             1.35
  kidney_cancer                                 467          716             1.53
  liver_cancer                                  950         1410             1.48
  lung_cancer                                   605          880             1.45
  lymphoma                                      16           21              1.31
  muscle_tissue_cancer                          692         1044             1.51
  ovarian_cancer                                351          512             1.46
  pancreas_insulinoma                           45           76              1.69
  pancreatic_cancer                             426          643             1.51
  primitive_neuroectodermal_cancer_of_CNS       659         1018             1.54
  prostate_cancer                               92           111             1.21
  prostatic_intraepithelial_neoplasia           11           18              1.64
  retinoblastoma                                434          705             1.62
  skin_cancer                                   939         1557             1.66
  stomach_cancer                                249          326             1.31
  uterus_cancer                                 128          179             1.40
  **Total**                                  **9,989**   **15,093**        **1.51**

10.1371/journal.pone.0004732.t004

###### Numbers of normal tissue-specific AS transcripts and their genes.

![](pone.0004732.t004){#pone-0004732-t004-4}

  Tissue types (35 tissues)     Genes     Transcripts   Transcripts/Gene
  --------------------------- ---------- ------------- ------------------
  bone-adult                      1            2               2
  brain-adult                    924         1613             1.75
  brain-fetus                    2231        5545             2.49
  brain-infant                    53          72              1.36
  colon-adult                     17          22              1.29
  colon-fetus                     1            2              2.00
  eye-adult                      582          907             1.56
  eye-fetus                       58          76              1.31
  heart-adult                     6            9              1.50
  heart-fetus                    100          146             1.46
  kidney-fetus                   110          142             1.29
  liver-adult                    335          961             2.87
  liver-fetus                    292          506             1.73
  lung-adult                      78          160             2.05
  lung-fetus                     110          152             1.38
  mammary-adult                   41          57              1.39
  muscle-adult                   250          384             1.54
  muscle-fetus                    18          27              1.50
  ovary-adult                     19          26              1.37
  pancreas-adult                  28          39              1.39
  pancreas-fetus                  23          33              1.43
  peripheral-nerve-adult          18          23              1.28
  peripheral-nerve-juvenile       18          23              1.28
  pituitary-gland-adult           28          84              3.00
  placenta-adult                 1567        2902             1.85
  prostate-adult                 102          162             1.59
  skin-infant                     99          121             1.22
  spleen-adult                    2            2              1.00
  spleen-fetus                    1            1              1.00
  stomach-adult                   3            5              1.67
  stomach-fetus                   1            6              6.00
  testis-adult                    47          73              1.55
  thyroid-adult                   16          20              1.25
  uterus-adult                    51          63              1.2
  vascular-adult                  10          10              1.00
  **Total**                    **7240**   **14,376**        **1.99**

To facilitate future studies and referencing of alternatively spliced genes, for both human cancer and normal tissues, we constructed a [h]{.ul}uman [c]{.ul}ancer- and normal tissue-[s]{.ul}pecific [a]{.ul}lternative [s]{.ul}plicing database (HCSAS) based on our analysis, which was divided into two parts: cancer-specific (15,093 transcripts) and normal tissue-specific (14,376) alternative splicing. Of these cancer- or tissue-specific AS, approximately 70% are novel isoforms. For example, in brain cancer, because of the alternative splicing and deletion of domain of the peptidase m20 family member, the aminoacylase-1 gene (ACY1) was spliced to produce a brain cancer-specific transcript ([Figure 1a](#pone-0004732-g001){ref-type="fig"}), and alternative splicing occurs in the SRP19 gene to produce a breast cancer-specific transcript by an alternative deletion of exon 3 ([Figure 1b](#pone-0004732-g001){ref-type="fig"}). Similarly, in liver cancer, lung cancer, and prostate cancer, cancer-specific isoforms were detected in our subtractive screening ([Figure 1c--e](#pone-0004732-g001){ref-type="fig"}).

![A schematic representation of cancer-specific alternative gene splicing.\
(a) Brain cancer (gene ACYl), (b) breast cancer (SRP19), (c) liver cancer (CDK5), (d) lung cancer (CDKN1A), and (e) prostate cancer (SMS). Cancer-specific isoforms are showed on the bottom in each panel. The biological processes of these transcripts (GO process) are indicated on the right. Deleted domains are shown with blue arrows. Arrows with a right angle indicate the start codon, ATG.](pone.0004732.g001){#pone-0004732-g001}

Furthermore, we systematically identified cancer-specific transcripts in both oncogenes and tumor suppressors. Thirty-nine oncogene isoforms and 38 tumor suppressor gene isoforms with cancer-specific AS events were detected ([Table 5](#pone-0004732-t005){ref-type="table"}). For example, we identified a lung cancer-specific transcript in the oncogene RAF1 with a deletion of the Raf-like Ras-binding domain, an uterus cancer-specific transcript in oncogene FOS ([Figure 2a](#pone-0004732-g002){ref-type="fig"}), and a retinoblastoma-specific transcript in the tumor suppressor GLTSCR2, and a skin-cancer-specific transcript in the tumor suppressor EMP3 ([Figure 2b](#pone-0004732-g002){ref-type="fig"}).

![A schematic representation of cancer-specific alternative gene splicing.\
(a) Oncogene, (b) tumor suppressor gene. The alternative splicing of RAF1 generates a lung cancer-specific transcript, whereas the alternative splicing of FOS produces an uterus cancer-specific transcript. Tumor suppressor GLTSCR2 is alternatively spliced to produce two retinoblastoma-specific transcripts and EMP3 to generate a skin cancer-specific transcript. Deleted domains are shown with blue arrows. Arrows with a right angle indicate the start codon, ATG.](pone.0004732.g002){#pone-0004732-g002}

10.1371/journal.pone.0004732.t005

###### Oncogenes and tumor suppressors with cancer-specific AS events.

![](pone.0004732.t005){#pone-0004732-t005-5}

  Gene ID                    Symbol                            Gene Description                             AS
  ----------------------- ------------ ----------------------------------------------------------------- --------
  **Oncogenes**                                                                                          
  25                          ABL1          v-abl Abelson murine leukemia viral oncogene homolog 1          1
  3726                        JUNB                           jun B proto-oncogene                           2
  7409                        VAV1                              vav 1 oncogene                              1
  6757                        SSX2                     synovial sarcoma, X breakpoint 2                     3
  2130                       EWSR1                     Ewing sarcoma breakpoint region 1                    3
  2241                        FER        fer (fps/fes related) tyrosine kinase (phosphoprotein NCP94)       2
  369                         ARAF             v-raf murine sarcoma 3611 viral oncogene homolog             1
  4613                        MYCN               v-myc myelocytomatosis viral related oncogene              2
  2534                        FYN                    FYN oncogene related to SRC, FGR, YES                  2
  727735                   unassigned               similar to TBC1 domain family member 3                  1
  51513                       ETV7                    ets variant gene 7 (TEL2 oncogene)                    2
  5894                        RAF1             v-raf-1 murine leukemia viral oncogene homolog 1             2
  4193                        MDM2      Mdm2, transformed 3T3 cell double minute 2, p53 binding protein     1
  4609                        MYC                v-myc myelocytomatosis viral oncogene homolog              1
  2353                        FOS            v-fos FBJ murine osteosarcoma viral oncogene homolog           3
  7410                        VAV2                              vav 2 oncogene                              1
  4194                        MDM4      Mdm4, transformed 3T3 cell double minute 4, p53 binding protein     1
  2118                        ETV4          ets variant gene 4 (E1A enhancer binding protein, E1AF)         3
  598                        BCL2L1                               BCL2-like 1                               3
  55885                       LMO3                   LIM domain only 3 (rhombotin-like 2)                   1
  3265                        HRAS            v-Ha-ras Harvey rat sarcoma viral oncogene homolog            2
  4893                        NRAS             neuroblastoma RAS viral (v-ras) oncogene homolog             1
                                                                   **Total**                              **39**
  **Tumor suppressors**                                                                                  
  5934                        RBL2                       retinoblastoma-like 2 (p130)                       1
  3482                       IGF2R                   insulin-like growth factor 2 receptor                  1
  5925                        RB1                  retinoblastoma 1 (including osteosarcoma)                1
  54984                    unassigned                     PIN2-interacting protein 1                        1
  4017                       LOXL2                           lysyl oxidase-like 2                           3
  29997                     GLTSCR2             glioma tumor suppressor candidate region gene 2             3
  2014                        EMP3                       epithelial membrane protein 3                      1
  672                        BRCA1                       breast cancer 1, early onset                       2
  54879                       ST7L                   suppression of cancerigenicity 7 like                  2
  51147                       ING4                   inhibitor of growth family, member 4                   1
  7982                        ST7                      suppression of cancerigenicity 7                     1
  51566                      ARMCX3                 armadillo repeat containing, X-linked 3                 4
  84695                      LOXL3                           lysyl oxidase-like 3                           2
  79961                     DENND2D                     DENN/MADD domain containing 2D                      2
  7157                        TP53                 cancer protein p53 (Li-Fraumeni syndrome)                1
  7248                        TSC1                           tuberous sclerosis 1                           1
  54768                      HYDIN                      hydrocephalus inducing homolog                      3
  581                         BAX                          BCL2-associated X protein                        1
  1026                       CDKN1A            cyclin-dependent kinase inhibitor 1A (p21, Cip1)             5
  1029                       CDKN2A                  cyclin-dependent kinase inhibitor 2A                   1
  10263                     CDK2AP2                        CDK2-associated protein 2                        1
                                                                   **Total**                              **38**

The HCSAS database presents a global overview of cancer-specific alternative splicing in humans and is essential for understanding tumorigenesis at a systematic level. The main information in this database includes the specific alternative splicing in both cancer and normal tissues, gene ID, gene structure, splicing sites, chromosome localization, DNA and protein sequences linked with the NCBI website, and GO process, function, and subcellular localization. An example page set shows the details of an adrenal cancer gene, FDPS ([Figure 3](#pone-0004732-g003){ref-type="fig"}). The HCSAS database can be accessed at <http://202.114.72.39/database/human.html>.

![A database of cancer- and normal tissue-specific alternative splicing.\
An example page set from the database shows the details of an adrenal cancer gene, FDPS. The information includes the specific alternative splicing of both cancer and normal tissues, gene ID, gene structure, splicing sites, chromosome localization, DNA and protein sequences linked with the NCBI website, and GO process, function, and subcellular localization.](pone.0004732.g003){#pone-0004732-g003}

Biased utilization of alternative splicing types in cancer {#s3b}
----------------------------------------------------------

An examination of cancer-specific alternative splicing revealed a biased distribution of alternative splicing types in cancer. Both the alternative 3′ splice site and 5′ splice site were used more often in cancer; however, a lower proportion of intron retention and cassette alternative exon occurred in cancer tissues compared to normal tissues ([Figure 4b](#pone-0004732-g004){ref-type="fig"}). Moreover, alternative splicing types differ between different kinds of cancer ([Figure 4a](#pone-0004732-g004){ref-type="fig"}). For example, in liver cancer, breast cancer, and prostate cancer, intron retention decreased and cassette alternative exons increased significantly, whereas in uterus cancer and skin cancer, cassette alternative exons markedly decreased.

![The frequencies (percentages) of the five types of cancer- and normal tissue-specific alternative splicing.\
(a) 16 types of human cancer and 17 normal tissues, (b) the average values between tumors and normal tissues. The five colors indicate the five types of tissue-specific alternative splicing: cassette alternative exon, alternative 5′ splice site, alternative 3′ splice site, intron retention, and mutually exclusive alternative exons. Yellowish regions indicate over 30% of the frequencies.](pone.0004732.g004){#pone-0004732-g004}

Preference in the selection of alternative splice sites in cancer {#s3c}
-----------------------------------------------------------------

To explore the preference/diversification of alternative splice sites in cancer, we analyzed all splice sites in the 27 types of cancer and 35 normal tissues by comparing each EST with its genomic sequence and mapping it onto the chromosome. We detected five basic donor-acceptor splice sites: GT-AG, CT-AC, GC-AG, GG-AG, and GT-GG, of which GT-AG are the most dominant sites. The others were classified into rare splice sites. We found that cancer uses rare splice sites and GT-AG more frequently, but less CT-AC compared to normal tissues ([Figure 5a, b](#pone-0004732-g005){ref-type="fig"}). Moreover, the selection of splice sites differs between different kinds of cancer ([Figure 5c](#pone-0004732-g005){ref-type="fig"}). For example, CT-AC sites are seldom used in breast cancer, liver cancer, lung cancer, and prostate cancer; in liver cancer, 5′ sites of rare splicing are almost AA.

![Percentages of the types of alternative splice sites.\
The splice sites include GT-AG, GC-AG, GG-AG, GT-GG, and the others (a) in human cancer (b) and normal tissues. (c) Percentage distribution of the splice sites in five types of cancer and normal tissues (brain, breast, lung, liver, and prostate).](pone.0004732.g005){#pone-0004732-g005}

Association of cancer-specific alternative splicing of both oncogenes and tumor suppressor genes with cancer {#s3d}
------------------------------------------------------------------------------------------------------------

Although both oncogenes and tumor suppressors are thought to be vital factors in tumorigenesis, we sought to identify cancer-specific variants and their possible involvement in cancer. We observed that oncogenes with cancer-specific AS are more often present in ovary cancer (6 oncogenes) and muscle cancer (5 oncogenes), whereas tumor suppressor genes with cancer-specific AS are more frequent in germ cell cancer (6), skin cancer (5), and primitive neuroectodermal cancer (5) ([Figure 6](#pone-0004732-g006){ref-type="fig"}). Some oncogenes and tumor suppressors with cancer-specific alternative splicing, such as EWSR1, CDKN1A, and GLTSCR2, are present in more types of cancer. Moreover, neither oncogenes nor tumor suppressors with cancer-specific AS were detected in brain cancer, prostate cancer, adrenal cancer, or lymphoma. This distribution bias for cancer-specific AS implies that the cancer-specific alternative splicing of both oncogenes and tumor suppressor genes is associated with specific cancer types.

![Distribution of oncogenes and tumor suppressors with cancer-specific alternative splicing in cancer.\
Blue squares indicate oncogenes, red squares indicate tumor suppressors, and yellow squares show both oncogenes and tumor suppressors.](pone.0004732.g006){#pone-0004732-g006}

Biological relevance of the cancer-specific transcripts in the diversification of protein functions {#s3e}
---------------------------------------------------------------------------------------------------

The cancer-specific transcripts were classified based on gene function by searching the RefSeq database and GO. We classified 15,093 cancer-specific transcripts from 9,989 genes into 15 function groups. Protein metabolism and modification, and nucleic acid metabolism are the most prevalent functional processes in cancer. However, the function groups of these cancer-specific transcripts differ in different cancers. For example, the least common process in breast cancer is pre-mRNA processing, whereas the function groups of cell communication and lipid, fatty acid, and steroid metabolism are seldom found in prostate cancer ([Figure 7](#pone-0004732-g007){ref-type="fig"}).

![Biological processes of alternatively spliced transcripts specific to cancer.\
The five cancer types are brain, breast, liver, lung, and prostate cancer. The numbers indicate the percentages for each process in the cancer. The GO process classification is based on the PANTHER (<http://www.pantherdb.org/tools/genexAnalysis.jsp>).](pone.0004732.g007){#pone-0004732-g007}

Discussion {#s4}
==========

The complexity of the transcriptome has been underestimated. In this paper, we described the transcriptome-wide identification and characterization of cancer-specific and alternatively spliced variants in human cancer based on a global view of cancer-specific alternative splicing developed by subtractive transcriptome-wide analysis. Based on an intersection/subtractive model, we have developed an analysis method for precisely screening cancer-specific alternative splicing. The EST sequences were aligned first, compared with their genomic sequences, and then mapped onto chromosomes. These procedures eliminated many EST errors, pseudogene, and multiple-copy/repeat gene problems when data were from diverse EST databases. Finally, the alternatively spliced transcripts were subject to the subtractive screening of a tissue versus all other tissues, and these analyses finally yielded cancer-specific transcripts. We identified a large number of cancer- / normal tissue-specific transcripts. Beyond all doubt, this is an abundant resource for research and the development of new diagnostic, prognostic, predictive, and therapeutic tools against human cancer. Furthermore, these resources are integrated into an available database. The HCSAS database presents a global overview of cancer-specific alternative splicing in humans and is essential for understanding tumorigenesis at a systematic level.

There are two main approaches for the global analysis of alternative splicing. First, based on the availability of sequenced genomes and large databases of sequenced transcripts (ESTs and cDNAs), alternative splicing events may be searched through reciprocal transcript alignments and alignments to genomic sequences. Several analyses in this manner have been reported [@pone.0004732-Modrek1], [@pone.0004732-Lee1]--[@pone.0004732-Brentani1]. Because of its major limitation of EST coverage bias, a microarray-based technology has been developed to search for the alternative splicing events [@pone.0004732-Johnson1], [@pone.0004732-Das1]--[@pone.0004732-Clark1]. Large sets of oligonucleotide probes may be designed specifically for individual exons and/or splice junction sequences, which allow the identification of new AS events. Here we have further developed a systematic method to search for cancer- or tissue-specific AS events in transcriptomes based on the intersection/subtractive screening analyses of transcriptomes, which is especially useful for identifying cancer/tissue-specific variants. Using this method, large numbers of cancer-specific isoforms were identified for the main human cancers. Nevertheless, these transcripts need to be further confirmed for their cancer/tissue specialization. RT-PCR technology and/or microarrays may be useful screening tools for this analysis.

Based on the transcriptome-wide analysis, we did observe special patterns of cancer-specific alternative splicing. 1) Less cancer-specific AS events occur in cancer compared to normal tissues. 2) Cancer possesses distribution bias for alternative splicing types. 3) Cancer uses rare splice sites and GT-AG more frequently, but less CT-AC compared to normal tissues. 4) The selection of splice sites differs between different kinds of cancer. 5) The cancer-specific alternative splicing of both oncogenes and tumor suppressor genes is associated with the specific cancer type. And finally, the functional groups of these cancer-specific transcripts differ in different cancers, indicating that individual cancers prefer combination controls of pathways in preference of using AS in tumorigenesis. These special features of human cancers indicate that 1) the cellular splicing machinery is changed during the transformation from normal to cancerous, 2) alternative splicing plays an important role during tumorigenesis, and 3) individual cancers have unique regulatory combinations at the alternative splicing level, which further support the prediction that approximately 60% of disease mutations in the human genome are splicing mutations [@pone.0004732-LopezBigas1], [@pone.0004732-Xing1]. Our data includes the discovery of many novel splice forms of cancer-associated genes and alternative-splicing patterns in cancer, and it suggests a significant new direction for human cancer research. We strongly advise the use of cancer-specific alternative splicing as a potential source of new diagnostic, prognostic, predictive, and therapeutic tools against human cancer. The global view of cancer-specific AS is not only useful for exploring the complexity of the cancer transcriptome, but it also widens the eyeshot of clinical research.
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